Department of Nephrology and Endocrinology, Japan Science and Technology Agency/Japan International Cooperation Agency, Science and Technology Research Partnership for Sustainable Development, the University of Tokyo, Tokyo, Japan.
Crit Care Med. 2010 Oct;38(10):2037-42. doi: 10.1097/CCM.0b013e3181eedac0.
This study is aimed to examine whether urinary L-type fatty acid-binding protein can detect the severity of sepsis with animal sepsis models and septic shock patients complicated with established acute kidney injury.
Experimental animal models and a clinical, prospective observational study.
University laboratory and tertiary hospital.
One hundred fourteen human L-type fatty acid-binding protein transgenic mice and 145 septic shock patients with established acute kidney injury.
Animals were challenged by abdominal (cecal ligation and puncture) and pulmonary (intratracheal lipopolysaccharide injection) sepsis models with different severities that were confirmed by survival analysis (n = 24) and bronchoalveolar lavage fluid analysis (n = 38).
In animal experiments, significant increases of urinary L-type fatty acid-binding protein levels were induced by sepsis (severe cecal ligation and puncture 399.0 ± 226.8 μg/g creatinine [n = 12], less-severe cecal ligation and puncture 89.1 ± 25.3 [n = 11], sham 13.4 ± 3.4 [n = 10] at 6 hrs, p < .05 vs. sham; 200 μg of lipopolysaccharide 190.6 ± 77.4 μg/g creatinine [n = 6], 50 μg of lipopolysaccharide 145.4 ± 32.6 [n = 8], and saline 29.9 ± 14.9 [n = 5] at 6 hrs, p < .05 vs. saline). Urinary L-type fatty acid-binding protein predicted severity more accurately than blood urea nitrogen, serum creatinine, and urinary N-acetyl-d-glucosaminidase levels. In clinical evaluation, urinary L-type fatty acid-binding protein measured at admission was significantly higher in the nonsurvivors of septic shock with established acute kidney injury than in the survivors (4366 ± 192 μg/g creatinine [n = 68] vs. 483 ± 71 [n = 77], p < .05). Urinary L-type fatty acid-binding protein showed the higher value of area under the receiver operating characteristic curve for mortality compared with Acute Physiology and Chronic Health Evaluation (APACHE) II and Sepsis-related Organ Failure Assessment (SOFA) scores (L-type fatty acid-binding protein 0.994 [0.956-0.999], APACHE II 0.927 [0.873-0.959], and SOFA 0.813 [0.733-0.873], p < .05).
Our results suggest that urinary L-type fatty acid-binding protein can be a useful biomarker for sepsis complicated with acute kidney injury for detecting its severity.
本研究旨在通过动物脓毒症模型和伴有已确诊急性肾损伤的脓毒性休克患者来检测尿型脂肪酸结合蛋白(L-FABP)是否可以检测脓毒症的严重程度。
实验动物模型和临床前瞻性观察研究。
大学实验室和三级医院。
114 名人类 L-FABP 转基因小鼠和 145 名伴有已确诊急性肾损伤的脓毒性休克患者。
通过不同严重程度的腹腔(盲肠结扎和穿刺)和肺(气管内脂多糖注射)脓毒症模型对动物进行挑战,通过生存分析(n=24)和支气管肺泡灌洗分析(n=38)进行确认。
在动物实验中,脓毒症诱导尿型 L-FABP 水平显著升高(严重盲肠结扎和穿刺 399.0±226.8μg/g 肌酐[n=12],轻度盲肠结扎和穿刺 89.1±25.3[n=11],假手术 13.4±3.4[n=10],6 小时时,p<.05 与假手术组相比;200μg 脂多糖 190.6±77.4μg/g 肌酐[n=6],50μg 脂多糖 145.4±32.6[n=8],生理盐水 29.9±14.9[n=5],6 小时时,p<.05 与生理盐水组相比)。尿型 L-FABP 比血尿素氮、血清肌酐和尿 N-乙酰-d-氨基葡萄糖苷酶水平更能准确预测严重程度。在临床评估中,伴有已确诊急性肾损伤的脓毒性休克患者入院时的尿型 L-FABP 明显高于幸存者(非幸存者 4366±192μg/g 肌酐[n=68],幸存者 483±71μg/g 肌酐[n=77],p<.05)。与急性生理学和慢性健康评估 II(APACHE II)和脓毒症相关器官衰竭评估(SOFA)评分相比,尿型 L-FABP 在死亡率方面的受试者工作特征曲线下面积(AUROC)值更高(L-FABP 0.994[0.956-0.999],APACHE II 0.927[0.873-0.959],SOFA 0.813[0.733-0.873],p<.05)。
我们的结果表明,尿型 L-FABP 可作为脓毒症合并急性肾损伤严重程度的有用生物标志物。